XML 60 R54.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting - Summary of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Revenue $ 11,175 $ 23,489 [1] $ 21,635 $ 45,128 [1]
Operating costs and expenses:        
Cost of goods sold 0 9,740 [1] 0 18,274 [1]
Clinical development, contract manufacturing and other third party costs 19,079 19,301 37,021 34,756
Employee costs 10,920 10,054 22,894 20,371
Facilities costs 2,968 4,106 6,326 8,638
Other operating costs 10,324 11,224 27,584 22,429
Other segment expenses 4,114 18,838 8,575 25,861
Total operating costs and expenses 47,405 73,263 [1] 102,400 130,329 [1]
Loss from operations (36,230) (49,774) [1] (80,765) (85,201) [1]
Non-operating income (expense):        
Non-cash interest expense on liabilities related to the sales of future royalties (5,394) (6,408) [1] (10,368) (11,939) [1]
Interest income 1,969 3,901 [1] 4,843 8,121 [1]
Other income (expense), net 260 (36) [1] 526 (135) [1]
Total non-operating income (expense), net (3,165) (2,543) [1] (4,999) (3,953) [1]
Loss before provision (benefit) for income taxes and equity method investment (39,395) (52,317) [1] (85,764) (89,154) [1]
Provision (benefit) for income taxes (188) 46 [1] (136) 11 [1]
Loss before equity method investment (39,207) (52,363) [1] (85,628) (89,165) [1]
Loss from equity method investment (2,386) 0 [1] (6,847) 0 [1]
Net loss (41,593) (52,363) [1] (92,475) (89,165) [1]
Rezpegaldesleukin (cytokine Treg stimulant)        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 12,930 12,099 26,733 20,983
NKTR-255 (IL-15 receptor agonist)        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 2,232 4,196 3,621 7,682
NKTR-0165 (tumor necrosis factor receptor type II agonist)        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 3,531 1,833 5,812 3,851
Discovery Research and Other Programs        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs $ 386 $ 1,173 $ 855 $ 2,240
[1] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).